Annual Net Income
-$33.78 M
-$8.37 M-32.93%
30 September 2022
Summary:
NeuBase Therapeutics annual net profit is currently -$33.78 million, with the most recent change of -$8.37 million (-32.93%) on 30 September 2022. During the last 3 years, it has fallen by -$8.37 million (-32.93%).NBSE Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
-$1.82 M
+$1.63 M+47.17%
30 September 2023
Summary:
NeuBase Therapeutics quarterly net profit is currently -$1.82 million, with the most recent change of +$1.63 million (+47.17%) on 30 September 2023.NBSE Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
-$13.73 M
+$5.81 M+29.74%
30 September 2023
Summary:
NeuBase Therapeutics TTM net profit is currently -$13.73 million, with the most recent change of +$5.81 million (+29.74%) on 30 September 2023.NBSE TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBSE Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -32.9% | +74.6% | +46.0% |
| 5 y5 years | -29.3% | +92.1% | +47.5% |
NBSE Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -6931.8% | -283.7% | -2877.7% |
NeuBase Therapeutics Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$1.82 M(-47.2%) | -$13.73 M(-29.7%) |
| June 2023 | - | -$3.45 M(-15.8%) | -$19.54 M(-20.5%) |
| Mar 2023 | - | -$4.09 M(-6.3%) | -$24.59 M(-19.2%) |
| Dec 2022 | - | -$4.37 M(-42.8%) | -$30.42 M(-9.9%) |
| Sept 2022 | -$33.78 M(+32.9%) | -$7.63 M(-10.1%) | -$33.78 M(+1.4%) |
| June 2022 | - | -$8.49 M(-14.4%) | -$33.30 M(-0.5%) |
| Mar 2022 | - | -$9.92 M(+28.4%) | -$33.47 M(+15.1%) |
| Dec 2021 | - | -$7.73 M(+8.0%) | -$29.07 M(+14.4%) |
| Sept 2021 | -$25.41 M(+46.2%) | -$7.16 M(-17.4%) | -$25.41 M(+10.7%) |
| June 2021 | - | -$8.66 M(+56.9%) | -$22.95 M(+26.9%) |
| Mar 2021 | - | -$5.52 M(+35.8%) | -$18.09 M(+6.7%) |
| Dec 2020 | - | -$4.07 M(-13.5%) | -$16.95 M(-2.5%) |
| Sept 2020 | -$17.38 M(-33.5%) | -$4.70 M(+23.7%) | -$17.38 M(-51.2%) |
| June 2020 | - | -$3.80 M(-13.2%) | -$35.64 M(+8.1%) |
| Mar 2020 | - | -$4.38 M(-2.8%) | -$32.98 M(+10.9%) |
| Dec 2019 | - | -$4.51 M(-80.4%) | -$29.74 M(+13.8%) |
| Sept 2019 | -$26.13 M(+97.4%) | -$22.96 M(+1926.3%) | -$26.13 M(+174.2%) |
| June 2019 | - | -$1.13 M(-0.9%) | -$9.53 M(+6.6%) |
| Mar 2019 | - | -$1.14 M(+27.3%) | -$8.94 M(-10.4%) |
| Dec 2018 | - | -$897.60 K(-85.9%) | -$9.98 M(-24.6%) |
| Sept 2018 | -$13.24 M(-44.4%) | -$6.36 M(+1066.2%) | -$13.24 M(+9.2%) |
| June 2018 | - | -$545.00 K(-75.1%) | -$12.13 M(-21.7%) |
| Mar 2018 | - | -$2.18 M(-47.4%) | -$15.48 M(-26.2%) |
| Dec 2017 | - | -$4.15 M(-20.8%) | -$20.99 M(-11.9%) |
| Sept 2017 | -$23.81 M(-7.6%) | -$5.24 M(+34.4%) | -$23.81 M(-5.5%) |
| June 2017 | - | -$3.90 M(-49.3%) | -$25.20 M(-13.1%) |
| Mar 2017 | - | -$7.69 M(+10.2%) | -$29.00 M(+9.0%) |
| Dec 2016 | - | -$6.98 M(+5.1%) | -$26.60 M(+3.2%) |
| Sept 2016 | -$25.77 M(+69.5%) | -$6.64 M(-13.8%) | -$25.77 M(+11.8%) |
| June 2016 | - | -$7.70 M(+45.7%) | -$23.04 M(+23.3%) |
| Mar 2016 | - | -$5.28 M(-14.0%) | -$18.69 M(+11.2%) |
| Dec 2015 | - | -$6.15 M(+57.2%) | -$16.80 M(+10.1%) |
| Sept 2015 | -$15.20 M(+66.4%) | -$3.91 M(+16.9%) | -$15.26 M(+5.7%) |
| June 2015 | - | -$3.35 M(-1.6%) | -$14.43 M(+9.9%) |
| Mar 2015 | - | -$3.40 M(-26.0%) | -$13.14 M(+12.2%) |
| Dec 2014 | - | -$4.60 M(+48.8%) | -$11.71 M(+28.2%) |
| Sept 2014 | -$9.13 M(+61.5%) | -$3.09 M(+50.7%) | -$9.13 M(+16.4%) |
| June 2014 | - | -$2.05 M(+4.2%) | -$7.84 M(+10.0%) |
| Mar 2014 | - | -$1.97 M(-2.7%) | -$7.13 M(+30.7%) |
| Dec 2013 | - | -$2.02 M(+12.1%) | -$5.46 M(-3.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2013 | -$5.65 M(+288.5%) | -$1.80 M(+34.7%) | -$5.65 M(+49.5%) |
| June 2013 | - | -$1.34 M(+357.9%) | -$3.78 M(+30.2%) |
| Mar 2013 | - | -$292.30 K(-86.8%) | -$2.90 M(-27.8%) |
| Dec 2012 | - | -$2.22 M(-3391.4%) | -$4.02 M(+176.6%) |
| Sept 2012 | -$1.45 M(-71.5%) | $67.40 K(-114.6%) | -$1.46 M(-49.5%) |
| June 2012 | - | -$460.80 K(-67.4%) | -$2.88 M(-48.2%) |
| Mar 2012 | - | -$1.41 M(-502.7%) | -$5.56 M(+29.2%) |
| Dec 2011 | - | $350.70 K(-125.8%) | -$4.30 M(-15.7%) |
| Sept 2011 | -$5.10 M(-1131.9%) | -$1.36 M(-56.7%) | -$5.10 M(+85.4%) |
| June 2011 | - | -$3.14 M(+1899.7%) | -$2.75 M(-1415.3%) |
| Mar 2011 | - | -$156.90 K(-65.0%) | $209.20 K(-1.5%) |
| Dec 2010 | - | -$448.80 K(-145.3%) | $212.30 K(-57.1%) |
| Sept 2010 | $494.40 K(-157.2%) | $991.50 K(-661.4%) | $494.30 K(-179.2%) |
| June 2010 | - | -$176.60 K(+14.8%) | -$623.80 K(-7.7%) |
| Mar 2010 | - | -$153.80 K(-7.8%) | -$676.20 K(-29.9%) |
| Dec 2009 | - | -$166.80 K(+31.8%) | -$964.70 K(+11.6%) |
| Sept 2009 | -$864.40 K(-3585.5%) | -$126.60 K(-44.7%) | -$864.30 K(-15.2%) |
| June 2009 | - | -$229.00 K(-48.2%) | -$1.02 M(+30.8%) |
| Mar 2009 | - | -$442.30 K(+566.1%) | -$778.90 K(+81.7%) |
| Dec 2008 | - | -$66.40 K(-76.4%) | -$428.60 K(-1828.2%) |
| Sept 2008 | $24.80 K(-100.4%) | -$281.20 K(-2656.4%) | $24.80 K(-78.2%) |
| June 2008 | - | $11.00 K(-112.0%) | $114.00 K(-103.6%) |
| Mar 2008 | - | -$92.00 K(-123.8%) | -$3.13 M(-32.9%) |
| Dec 2007 | - | $387.00 K(-301.6%) | -$4.66 M(-8.6%) |
| Sept 2007 | -$6.30 M(<-9900.0%) | -$192.00 K(-94.1%) | -$5.10 M(+3.7%) |
| June 2007 | - | -$3.23 M(+98.8%) | -$4.91 M(+206.1%) |
| Mar 2007 | - | -$1.63 M(+3130.6%) | -$1.61 M(-2616.5%) |
| Dec 2006 | $63.70 K(-16.1%) | -$50.30 K(+452.7%) | $63.80 K(-36.5%) |
| Sept 2006 | - | -$9100.00(-111.5%) | $100.40 K(-48.0%) |
| June 2006 | - | $78.90 K(+78.1%) | $192.90 K(+131.3%) |
| Mar 2006 | - | $44.30 K(-423.4%) | $83.40 K(-18.7%) |
| Dec 2005 | $75.90 K(-42.1%) | -$13.70 K(-116.4%) | $102.60 K(+157.8%) |
| Sept 2005 | - | $83.40 K(-372.5%) | $39.80 K(+563.3%) |
| June 2005 | - | -$30.60 K(-148.2%) | $6000.00(-95.4%) |
| Mar 2005 | - | $63.50 K(-183.0%) | $129.20 K(-1.4%) |
| Dec 2004 | $131.10 K(+28.7%) | -$76.50 K(-254.2%) | $131.10 K(-36.8%) |
| Sept 2004 | - | $49.60 K(-46.4%) | $207.60 K(+31.4%) |
| June 2004 | - | $92.60 K(+41.6%) | $158.00 K(+141.6%) |
| Mar 2004 | - | $65.40 K | $65.40 K |
| Dec 2003 | $101.90 K | - | - |
FAQ
- What is NeuBase Therapeutics annual net profit?
- What is the all time high annual net income for NeuBase Therapeutics?
- What is NeuBase Therapeutics quarterly net profit?
- What is the all time high quarterly net income for NeuBase Therapeutics?
- What is NeuBase Therapeutics TTM net profit?
- What is the all time high TTM net income for NeuBase Therapeutics?
What is NeuBase Therapeutics annual net profit?
The current annual net income of NBSE is -$33.78 M
What is the all time high annual net income for NeuBase Therapeutics?
NeuBase Therapeutics all-time high annual net profit is $494.40 K
What is NeuBase Therapeutics quarterly net profit?
The current quarterly net income of NBSE is -$1.82 M
What is the all time high quarterly net income for NeuBase Therapeutics?
NeuBase Therapeutics all-time high quarterly net profit is $991.50 K
What is NeuBase Therapeutics TTM net profit?
The current TTM net income of NBSE is -$13.73 M
What is the all time high TTM net income for NeuBase Therapeutics?
NeuBase Therapeutics all-time high TTM net profit is $494.30 K